Form 4: Scholar Rock Director Richard Brudnick Reports Significant Equity Grant

Scholar Rock Holding Corp. Director Richard Brudnick has reported the acquisition of 7,632 restricted stock units and 9,206 stock options as part of his compensation, increasing his beneficial ownership in the company.

Summary

• Richard Brudnick, a Director of Scholar Rock Holding Corp. (SRRK), reported new equity grants on May 22, 2025.
• He acquired 7,632 Restricted Stock Units (RSUs) at a price of $0.00 per unit, which represent the contingent right to receive one share of common stock upon vesting.
• These RSUs are set to vest on the earlier of June 15, 2026, or the date of the Issuer's next Annual Meeting, subject to his continued service to the Issuer.
• Mr. Brudnick also acquired 9,206 stock options with an exercise price of $30.46 per share.
• These stock options will vest and become fully exercisable on the earlier of the first anniversary following the grant date or the date of the Issuer's next Annual Meeting, also subject to continued service, and have an expiration date of May 22, 2035.
• Following these transactions, Mr. Brudnick beneficially owns a total of 21,132 shares of common stock, which includes 13,500 direct shares and the 7,632 RSUs.
• He also beneficially owns 9,206 stock options.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. This Form 4 reports a routine equity grant to a director, which aligns their interests with shareholders and is a standard compensation practice. It does not indicate any immediate operational or financial changes, but rather reinforces long-term commitment.

Positives

• The grant of restricted stock units and stock options to Director Richard Brudnick aligns his interests with those of shareholders, incentivizing long-term performance and commitment to the company's success.
• The acquisition of equity at a $0 price for RSUs and a specific exercise price for options indicates compensation-related grants, which is a standard and expected practice for director remuneration, reflecting ongoing engagement and value creation.

Negatives

• No direct negatives are apparent from this Form 4 filing, as it reports an acquisition of equity by an insider, which is typically viewed as a neutral to positive event.

Risks

• The vesting of both the 7,632 Restricted Stock Units (RSUs) and the 9,206 stock options is contingent upon Richard Brudnick's continued service to Scholar Rock Holding Corp. through the specified vesting dates. Should his service terminate prior to vesting, these unvested awards would be forfeited.

Future Outlook

The future outlook, as indicated by the vesting schedules, suggests a continued alignment of Director Richard Brudnick's interests with the company's long-term performance. The Restricted Stock Units (RSUs) are set to vest by June 15, 2026, or the next Annual Meeting, and the stock options will vest by the first anniversary of the grant or the next Annual Meeting, both contingent on his continued service.

Industry Context

The grant of equity compensation, including restricted stock units and stock options, to directors is a common and widely accepted practice across the biotechnology and pharmaceutical industries. This strategy is employed by companies like Scholar Rock Holding Corp. to attract, retain, and incentivize key personnel, ensuring their long-term interests are aligned with the company's strategic objectives and shareholder value creation.

Comparison to Industry Standards

• The compensation structure involving RSUs and stock options for directors is a standard practice across publicly traded companies, particularly within the biotechnology sector.
• While specific comparable companies or projects are not detailed in this filing, such equity grants are typical for non-employee directors in companies like Biogen Inc., Vertex Pharmaceuticals Inc., or Sarepta Therapeutics, Inc., aiming to align director incentives with long-term shareholder value.
• The specific value and vesting terms of these grants would typically be benchmarked against peer groups in compensation studies to ensure competitiveness and appropriateness within the industry.

Stakeholder Impact

• Shareholders: The equity grants to a director are designed to align management's long-term interests with those of shareholders, potentially leading to improved governance and strategic decisions aimed at increasing shareholder value.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• Vesting of 7,632 Restricted Stock Units (RSUs) on the earlier of June 15, 2026, or the date of the Issuer's next Annual Meeting, subject to continued service.
• Vesting of 9,206 Stock Options on the earlier of the first anniversary of the grant date or the date of the Issuer's next Annual Meeting, subject to continued service.
• Potential exercise of stock options by Richard Brudnick at the exercise price of $30.46 per share once vested and exercisable.

Key Dates

Recommendation

Keywords

Scholar Rock Holding Corp, SRRK, SEC Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Director Compensation, Richard Brudnick